Short Description:
Product Name: 2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE
CAS NO.: 81058-27-7
Synonyms:
Canagliflozin Intermediate 3
TETRAKIS(2,2-DIMETHYLPROPANOATE)-A-D-GLUCOPYRANOSYL BROMIDE
Related Categories: Pharmaceutical intermediates, pharmaceutical raw materials, canagliflozin intermediates
Application
Canagliflozin intermediates, it can be used to prepare canagliflozin. Canagliflozin is the first FDA-approved SGLT2 inhibitor drug, which can lower blood sugar by breaking down glucose and excreting it through the kidneys, and is used to treat type 2 diabetes in adults
Supply Ability
2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE CAS NO.81058-27-7 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
Contact Information
If you are interested in 2,3,4,6-TETRA-O-PIVALOYL-ALPHA-D-GLUCOPYRANOSYL BROMIDE CAS NO.81058-27-7, feel freely contact us please, and we will provide you the best quality products, reasonable price and best service, expecting to our cooperation.
Company Profile
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is a subsidiary of Shenzhen Rich Chemical Technology Co., Ltd., located in Shanghai. Since its establishment, Lizhuo Pharmaceutical has been committed to providing global pharmaceutical companies and new drug research and development institutions with comprehensive solutions from early product development to drug listing. R&D, customization and production services of pharmaceutical intermediates and APIs required in the life cycle.
Lizhuo Pharmaceutical is a comprehensive technology enterprise focusing on the R&D, production and sales of pharmaceutical intermediates, mainly developing and producing anti-tumor, psychotropic, antiviral, hypoglycemic and antibacterial pharmaceutical intermediates. Our company also engaged in developing innovative drug intermediates according to the situation of the new drug market, and at the same time, develop and customize new drug intermediates according to the needs of customers.
Our company has a complete R&D, pilot and scale-up production base. Currently, we have one 1,000-square-meter R&D laboratory, 2 pilot production workshops in Wuhan, equipped with twenty 50L-1000L reactors, high and low temperature Circulation device (-40°C-200°C), ultra-low temperature reaction device (-120°C), vacuum and atmospheric distillation tower (2-6 meters), molecular distillation, solid distillation and other advanced equipment, can undertake ultra-low temperature reaction, format Continuous reaction, nitration reaction, nitro reduction reaction, epoxidation synthesis reaction, solid-liquid distillation and rectification and other production processes, the research and development center can undertake the customization of pharmaceutical intermediates from grams to kilograms, and the pilot production workshop and factory can Produce hundreds of kilograms to tons of products.
The production base is located in Hubei, with sufficient chemical raw materials and very convenient transportation. Covering an area of 120 acres, it has high temperature, low temperature, ultra-low temperature, fixed bed and other large-scale reaction equipment, and has multi-stage rectification equipment and a complete set of separation and drying equipment, with an annual production capacity of more than 500 tons of fine chemicals.
Media Contact
Company Name: Shanghai Lizhuo Pharmaceutical Technology Co.,Ltd.
Email: Send Email
Country: China
Website: https://www.shlzpharma.com/
